David S. Ettinger, MD, FACP, FCCP (Course Chair)
Alex Grass Professor of Oncology
The Johns Hopkins University School of Medicine
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Suresh S. Ramalingam, MD (Faculty)
Department of Hematology and Medical Oncology
Director of Thoracic Oncology, Winship Cancer Institute
Estimated amount of time to complete: 30 minutes
Lung cancer is the leading cause of worldwide cancer mortality and is responsible for more deaths annually in the United States than the combination of breast, colorectal, and prostate cancer. Almost 85% of lung cancers are classified as non-small-cell lung cancer (NSCLC), and up to 70% of NSCLC present as locally advanced (stage III) or metastatic disease (stage IV).
Treatment approaches based on personalized medicine, targeted therapies, and tumor histologies represent a significant advance in the treatment of NSCLC. There is a significant need to educate oncologists on molecular markers in the pathogenesis of NSCLC, as well as the role of histology in treatment response to various agents for patients with advanced NSCLC.
Case Studies in Lung Cancer: A Johns Hopkins Oncology Newsletter Series utilizes case-based articles focusing on key treatment concepts in NSCLC. Presentations of patient cases and discussion of relevant treatment dilemmas and options by a distinguished faculty of oncologists are designed to update you on the latest clinical trial results and their
implications for clinical practice. Target Audience
This educational activity is designed to meet the needs of oncologist, pathologists, and other healthcare professionals involved or interested in the treatment of patients with lung cancer.
Upon completion of this educational activity, the participant should be able to:
Evaluate recent trends in tailoring treatment decisions based on NSCLC histology.
Individualize treatment regimens based on patient and/or tumor characteristics.
Examine the role of maintenance/sequential therapy for patients with NSCLC.
As a provider accredited by the Accreditation Council for Continuing Medical Education (ACCME), it is the policy of Johns Hopkins University School of Medicine to require the disclosure of the existence of any relevant financial interest or any other relationship a faculty member or a provider has with the manufacturer(s) of any commercial product(s) discussed in an educational presentation. The presenting faculty reported the following;
David Ettinger: Consultant and Honoraria: AstraZeneca, Bristol-Myers Squibb, Celgene, Eli Lilly, Eisai, Genentech, GlaxoSmithKline, ImClone, Merck,and Novartis.
Suresh Ramalingam: Consultant: Amgen, Astellas, Genentech, GlaxoSmithKline, ImClone, and Syndax.
Off-Label Discussions: This newsletter series references unlabelled/ unapproved uses of: Erlotinib, combination therapies: cetuximab + cisplatin/vinorelbine; erlotinib + bevacizumab.
Accreditation Statement: The Johns Hopkins University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation Statement: The Johns Hopkins University School of Medicine designates this educational activity for a maximum of 0.50 AMA PRA Category 1 Credit TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
To receive your CME credit certificate,complete the post-test and evaluation, and document the amount of time you spent in the activity. Participants receiving a grade of 80% or higher will receive a CME certificate.
Commercial Support Statements
This continuing medical education activity is made possible by an educational grant from Genentech, Inc.
© 2010: All Rights Reserved – The Johns Hopkins University School of Medicine
The opinions and recommendations expressed by faculty and other experts whose input is included in this program are their own. This enduring material is produced for educational purposes only. Use of Johns Hopkins University School of Medicine name implies review of educational format design and approach. Please review the complete prescribing information of specific drugs or combination of drugs, including indications, contraindications, warnings and adverse effects before administering pharmacologic therapy to patients.